肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

TCGA数据库使用教程：官网、数据下载与数据挖掘分析

2020-08-15 网络 网络

数据挖掘TCGA数据库
关注

肿瘤基因组图谱 (TCGA) 计划由美国 National Cancer Institute(NCI) 和 National Human Genome Research Institute（NHGRI

肿瘤基因组图谱 (TCGA) 计划由美国 National Cancer Institute(NCI) 和 National Human Genome Research Institute（NHGRI）于 2006 年联合启动的项目，其主要收录各种人类癌症（包括亚型在内的肿瘤）的临床数据，基因组变异，mRNA表达，miRNA表达，甲基化等数据，是癌症研究者很重要的数据来源，目前共计研究 36 种癌症类型。 TCGA 利用大规模测序为主的基因组分析技术，通过广泛的合作，理解癌症的分子机制。提高人们对癌症发病分子基础的科学认识及提高我们诊断、治疗和预防癌症的能力。 最终完成一套完整的与所有癌症基因组改变相关的「图谱」。 一、TCGA数据库说明与数据下载  首先，TCGA官网：https://cancergenome.nih.gov/abouttcga/overview 1. 数据等级： TCGA存储的数据可分为三个级别： Level 1: 原始的测序数据（fasta,fastq等） Level 2:比对好的bam文件 Level 3:为经过处理及标准化的数据 Level

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2023-12-03 ms6000002093617293 来自浙江省

    想看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2021-07-14 ms6000000525429959

    想看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2021-05-12 ms9000001273488727

    想看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-10-25 ms4000001327670760

    写的很有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-16 翟子卿

    写得还可以哦

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2172621, encodeId=018c21e262106, content=想看 , beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e8721207, createdName=ms6000002093617293, createdTime=Sun Dec 03 09:24:55 CST 2023, time=2023-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=999471, encodeId=75719994e18e, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81f75548946, createdName=ms6000000525429959, createdTime=Wed Jul 14 17:18:11 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964855, encodeId=2ca296485565, content=想看, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3795499197, createdName=ms9000001273488727, createdTime=Wed May 12 11:22:56 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894310, encodeId=2d1d89431069, content=写的很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/18a7e075a76b4eba91ce1e836a4630ca/fe5a667d922447dba10e1f272b4fb394.jpg, createdBy=fa235428865, createdName=ms4000001327670760, createdTime=Sun Oct 25 14:46:48 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809325, encodeId=806d809325b2, content=写得还可以哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/c5af155ca6f940de80aba933d001e95e/c3c5d6ef5cd941d48a411f04f9125882.jpg, createdBy=5d291638320, createdName=翟子卿, createdTime=Sun Aug 16 11:10:36 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809320, encodeId=f4ff809320d1, content=不错不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/963dd135fa21481baf82fb4f4e054cd2/1389792cce544582809a6851932681dc.jpg, createdBy=d67f5411216, createdName=浪迹天涯2020, createdTime=Sun Aug 16 10:22:43 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-16 浪迹天涯2020

    不错不错哦

    0

相关资讯

基于数据挖掘的《理虚元鉴》用药规律研究

分析《理虚元鉴》用药规律，探讨汪绮石治疗虚证用药特点及辨治思路，为临床提供参考。

案例精讲：甲基化与基因表达数据挖掘的思路与过程

口腔鳞状细胞癌（OSCC）是最常见的头颈部鳞状细胞癌（HNSCC），由于对OSCC的发生、发展、进展、侵袭和转移的理解有限，导致该病的早期诊断大大延迟。因此，鉴定与OSCC相关的重要癌基因或肿瘤抑制基

R进行数据统计与数据挖掘：手把手教你！

R是一种广泛用于数据分析和统计计算的强大语言，于上世纪90年代开始发展起来。得益于全世界众多爱好者的无尽努力，大家继而开发出了一种基于R但优于R基本文本编辑器的R Studio(用户的界面体验更好)。也正是由于全世界越来越多的数据科学社区和用户对R包的慷慨贡献，让R语言在全球范围内越来越流行。其中一些R包， 例如MASS，SparkR， ggplot2，使数据操作,可视化和计算功能越来越强大。

数据挖掘在医学上的应用

本篇将再多讲一讲数据挖掘在医学上的应用，希望能对感兴趣的朋友有所启发，也供从事其他行业数据挖掘应用的同仁参考。 数据挖掘，又称知识发现（KDD），是从大量的数据中抽取潜在的、有价值的知识的过程。数据挖掘所探寻的模式是一种客观存在的、但隐藏在数据中未被发现的知识。例如，数据挖掘可直接挖掘疾病高发人群，发现疾病及症状间的未知联系，探索化验指标间的影响关系及化验指标与疾病间的潜在影响，对未知的

数据挖掘算法全景图——Clementine12.0算法

                                 &n

数据挖掘与虚拟医药科研

我们在前面的博客里初步谈论了一些数据挖掘的实践应用。我们说数据挖掘的应用很广泛，在某些领域也已很成熟，实用价值很高。其中数据挖掘在医药学领域就有一些比较成熟可靠的应用了。但有时，我们也听说有些人将数据挖掘在某些领域的应用说成是“讲故事”。这实际上是反映了这些案例的开发和应用很不成熟，可信度很低。成熟的数据挖掘应用绝不是“讲故事”。本人在北美工作了多年，从来没有听说过数据挖掘是“讲故事”（也许是